Authored by Jingduan Yang via The Epoch Times (emphasis ours),

“Was I misled?”

That’s the question I hear most from my patients lately—asked with anger, exhaustion, and the quiet devastation of women who wonder if they lost years of their lives to menopause symptoms they were told were untreatable.

The answer came earlier this month when the U.S. Food and Drug Administration announced it would remove “black box” warnings from hormone therapy products after 23 years. For many women, the reversal is an admission that arrives decades too late.

What Happened in 2002

In July 2002, preliminary data from the Women’s Health Initiative (WHI) were published in JAMA, showing that combined hormone therapy (estrogen and progestin) increased the risk of breast cancer, stroke, and pulmonary embolism. Major media outlets interpreted early signals from the study as definitive danger, and the announcement led to an instant and dramatic decline in the use of hormone therapy.

Women who had been sleeping well for the first time in years suddenly poured their medications into the trash. Pharmacies fielded calls from panicked patients demanding immediate discontinuation. Primary care doctors, most of whom had never been trained deeply in menopause management, told their patients to “stop now and ask questions later.”

Women did stop, and many suffered in silence for the next 20 years.

The FDA’s Historic Reversal

On Nov. 10, the FDA announced that it is initiating the removal of broad “black box” warnings referencing risks of cardiovascular disease, breast cancer, and probable dementia from hormone replacement therapy products for menopause.

When FDA Commissioner Dr. Marty Makary spoke publicly about the shift, he didn’t mince words. He said the media had frightened women away from a potentially life-changing therapy, and he noted the difference between estrogen-only therapy and synthetic combination regimens. He acknowledged, openly, that the “fear machine” had begun long before the scientific data had been fully understood.

He also said something that struck many women deeply: “After 23 years of dogma, the FDA is stopping the fear that has steered women away from this life-saving treatment.”

For many of my patients, that sentence felt like a validation they had waited half a lifetime to hear.

The Devil Is in the Details

The details that matter most sat quietly in the medical literature for years—in the 2002 article and the two follow-up studies published in 2011 and 2020 in JAMA.

The Study Population Was Older

Women recruited in the WHI study were all postmenopausal, aged 50 to 79 years, with an average age of 63—more than a decade past the onset of menopause. Most had not used hormones before, and many had cardiovascular risk factors.

The Hormones Were Synthetic

The adverse results found among older women taking combined conjugated equine estrogen and medroxyprogesterone acetate—both older, synthetic formulations developed in a different era—were generalized to all hormone therapy types and all age groups.

Estrogen-Only Therapy Showed Different Results

The estrogen-only group in the WHI study—women who had hysterectomies and therefore received estrogen without synthetic progestins—had a lower rate of breast cancer.

In the storm of fear that followed, no one wanted to hear nuance.

The Critical Factor

Yet even in the early 2000s, there were physicians who paused, confused because something about the reporting didn’t align with what they were seeing clinically. The hormones used in the WHI study weren’t the bioidentical estradiol and progesterone that many clinicians were already prescribing with good results. More importantly, the women who seemed to benefit most from hormone therapy were those who began it near menopause—not in older age.

Timing is critical. The body responds to estrogen very differently pre-menopause versus a decade post-menopause. After years of low estrogen, the blood vessels lose their flexibility, plaque accumulates, and metabolic changes settle in. The risk-benefit balance is fundamentally different for women who initiate hormone therapy at different ages.

This is what we in medicine now call the “timing hypothesis”—a concept that should have been central to every headline but was lost entirely.

And for two decades, women lived inside that headline and endured the consequences of fear and misinformation.

What Women Lost

The point is not that hormone therapy is perfect or appropriate for everyone. It’s that women were never given the chance to make an informed choice.

Women who begin hormone therapy earlier—ideally within 10 years of menopause—tend to experience improved sleep, reduced anxiety and irritability, and protection against bone loss.

Many report better cognition, improved cardiovascular markers, and enhanced sexual health and relationship well-being. Although spoken about more quietly, perhaps the most profound benefit is the simplest one: the return of themselves.

Takeaways

The new FDA guidelines do not signal a new fad or a sudden reversal. They mark a return to evidence-based medicine—the kind that millions of women should have received all along.

Hormone therapy is not appropriate for every woman, and it is not a cure-all. However, it is a powerful tool, and for the right woman at the right moment, it can restore a quality of life she thought she’d lost forever.

Our job now—as clinicians, as journalists, as a society—is to give women back what fear took from them: clarity, choice, and control.

Everything that follows in this series of columns will build on that mission.